logo
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.

Globe and Mail18-05-2025

Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal. A recent study from Ned Davis Research and Hartford Funds found that companies able to grow their dividends over time have historically delivered higher total returns with less volatility than those that merely held steady or slashed their payouts.
With that in mind, let's take a closer look at three stocks to avoid due to their shaky dividend outlooks.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
1. AbbVie
AbbVie (NYSE: ABBV) is a pharmaceutical company with a $300 billion market capitalization known for manufacturing popular drugs Skyrizi and Botox. The stock, down 16% year to date, pays a quarterly dividend of $1.64 per share, representing an annual yield of 3.5%.
While AbbVie's management has paid and raised its dividend for 11 consecutive years, it currently has a payout ratio -- the percentage of earnings paid out as dividends -- of 266%. Generally, if a payout ratio stays above 75% for a significant period, it is in danger of being slashed or paused.
One reason why AbbVie's payout ratio has skyrocketed is that one of its drugs, Humira, a drug to treat rheumatoid arthritis, faces steeper competition. As a result, its sales have been on a nose dive, down 51% to $1.1 billion in fiscal Q1 2025 compared to fiscal Q1 2024. With the loss in sales, AbbVie's net income has plummeted, generating $4.2 billion over the trailing 12 months, or approximately 69% from its highs a few years ago.
Combined with those financials, its net debt has climbed 24% over the past two years to $64.7 billion, and the future of its dividend is in doubt.
ABBV Net Income (TTM) data by YCharts.
On the bright side, AbbVie's next-generation immunology drugs Skyrizi and Rinvoq are growing tremendously. In fiscal Q1 2025 alone, they brought in a combined $5.1 billion -- a 65% increase from the prior year. For the full fiscal year, management expects Skyrizi to generate $16.5 billion and Rinvoq $8.2 billion, marking year-over-year growth of 41% and 37%, respectively.
Still, it's unclear whether this momentum will offset Humira's decline and reignite overall earnings growth.
2. Medtronic
Medtronic (NYSE: MDT) is a medical device company known for cardiac devices, surgical robotics, insulin pumps, and surgical tools. Like many healthcare companies, its stock soared during the COVID-19 pandemic and hasn't recovered since, down 37% from its 2021 highs.
The company is a historical dividend-paying stock, having paid and raised its dividend for an astounding 47 consecutive years. Today, the company pays a quarterly dividend of $0.70 per share, equating to an annual yield of 3.3%. Historically, Medtronic has announced its dividend hikes during its Q4 earnings release, which is slated for May 21. Whereas the increase used to be a certainty, now there are some question marks as it faces increased competition, ongoing supply chain struggles, and patient lawsuits related to spinal cord stimulation technologies.
Medtronic has a high payout ratio of 84.7% on the heels of declining net income in its most recently reported quarter. Specifically, the company reported a net income of $1.29 billion in fiscal Q3 2024, representing a 2% year-over-year decline.
Zooming out, the company's net income hasn't grown significantly in a decade despite revenue reaching all-time highs. This is partly due to Medtronic's acquisitive nature, which has completed over 60 acquisitions, with management focusing on "tuck-in acquisitions," designed to help grow and improve margins.
MDT Net Income (Quarterly) data by YCharts.
Additionally, the company currently holds $18.6 billion in net debt, with servicing costs totaling $757 million over the past 12 months. On the positive side, management has reduced debt by 8% from recent highs and repurchased 3.7% of shares outstanding since 2024 -- moves that help support the sustainability of its dividend. However, whether the company can grow its dividend over the long term remains uncertain.
3. Pfizer
Pfizer (NYSE: PFE) is one of the most well-known pharmaceutical companies on the market due to its 176-year history and, more recently, for its involvement in the manufacturing and distribution of a COVID-19 vaccine. The latter reason is also why the company is at a crossroads today and why the future of its dividend is in doubt.
Currently, Pfizer offers a quarterly dividend of $0.43 per share, equating to an outsized annual yield of 7.6% as its stock has fallen 63% from its pandemic highs. While that yield is certainly attractive for dividend investors, its payout ratio of 121.5% casts doubt on whether management can raise it for the 17th straight year. Notably, Pfizer has paid 346 consecutive quarterly dividends, but it did cut its dividend in 2009 to help fund the acquisition of the pharmaceutical company Wyeth for $68 billion.
More recently, Pfizer reported an 8% decline in revenue for Q1 2025, delivering only $13.7 billion compared to $14.9 billion in Q1 2024. Pfizer's COVID-19 product, Paxlovid, led the decline, falling from $2 billion to $491 million, or a decrease of 76%.
In the long term, management will likely continue spending heavily on research and development; it has averaged more than $10 billion over the past few years as it looks to find its next breakthrough drug. In the meantime, management has suspended its share repurchases as it continues to pay down its $44 billion in net debt. The good news is that management has deleveraged the company by 31% in less than a year.
PFE Net Financial Debt (Quarterly) data by YCharts.
Are these high-yield dividend stocks worth buying?
These three stocks have much in common beyond the pharmaceutical industry in which they operate. For dividend-seeking investors, while their yields are attractive, it's important to recognize their associated risks. Considering that and the unfavorable history of stocks that cut or paused their dividends, investors should avoid them for now.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $642,582!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $829,879!*
Now, it's worth noting Stock Advisor 's total average return is975% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 12, 2025
Collin Brantmeyer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?
PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?

Globe and Mail

time27 minutes ago

  • Globe and Mail

PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?

PepsiCo, Inc. 's PEP hydration portfolio is anchored by Gatorade and LIFEWTR, two brands that reflect its strategic shift toward functional performance and premium wellness offerings. In first-quarter 2025, Gatorade remained a strong performer, especially with innovations like Gatorade Zero and new rapid hydration products. The company is also investing in powders, tablets and other functional hydration options to meet evolving health and wellness demands. Gatorade's ongoing expansion into performance-focused formats is helping it regain its share in the competitive sports drink market. LIFEWTR, PepsiCo's premium bottled water brand, is another pillar of the company's health-focused strategy. Positioned as a wellness-driven offering, LIFEWTR taps into the growing consumer interest in premium hydration with clean ingredients and lifestyle-oriented branding. The brand's continued double-digit growth demonstrates strong traction, supporting PepsiCo's broader efforts to diversify away from traditional sugary beverages. This approach aligns with the company's intention to offer more permissible, functional beverages across a range of consumer occasions. Complementing these efforts is PepsiCo's broader shift toward 'better-for-you' portfolios, which include investments in protein, fiber and reduced sugar offerings. Notably, the company is innovating in protein-enriched beverages and snacks, aiming to capture value in emerging consumption trends, such as those driven by GLP-1 medication users seeking smaller portions and nutrient-dense foods. With consumer demand moving toward healthier, more functional products, PepsiCo's strategy of doubling down on brands like Gatorade and LIFEWTR positions it well for sustained growth in the wellness space. PEP's Competition in the Wellness Space The Coca-Cola Company KO and Keurig Dr Pepper KDP are the key beverage companies competing with PepsiCo in the global arena. The Coca-Cola Company is strategically reinforcing its hydration and wellness lineup to compete directly with PepsiCo's Gatorade and LIFEWTR by leveraging brands like Powerade, Smartwater and Vitaminwater. Powerade has been revamped with a focus on innovation in performance hydration, incorporating enhanced electrolytes and new formulations to target athletes and fitness enthusiasts. Smartwater and Vitaminwater continue to lead Coca-Cola's charge in the premium and functional beverage segments, respectively, offering vapor-distilled purity and added nutrients. The company is also investing in digital marketing, packaging personalization and local relevance campaigns to build consumer trust and loyalty. With 30 billion-dollar brands in its portfolio and 68% of its drinks containing fewer than 100 calories per serving, Coca-Cola is aligning with health trends through innovation and consumer-centric strategies, positioning itself as a strong challenger to PepsiCo's hydration dominance. Keurig Dr Pepper competes aggressively with PepsiCo in the hydration and wellness space through brands like Core Hydration and Snapple Elements, focusing on functional benefits and health-conscious positioning. KDP's strategy centers on leveraging consumer trends such as low-calorie, antioxidant-rich and pH-balanced beverages, positioning Core as a premium hydration brand. Innovation remains a cornerstone of its approach, with ongoing flavor expansions, clean-label formulations and sleek packaging aimed at wellness-driven Millennials and Gen Z consumers. By capitalizing on its broad distribution network and agile marketing, KDP is carving out a strong niche against PepsiCo's Gatorade and LIFEWTR, appealing to consumers looking for alternatives with perceived health benefits and contemporary branding. PEP's Price Performance, Valuation and Estimates Shares of PepsiCo have lost around 14.5% year to date against the industry 's growth of 7.6%. From a valuation standpoint, PEP trades at a forward price-to-earnings ratio of 16.13X, significantly below the industry's average of 18.68X. The Zacks Consensus Estimate for PEP's 2025 earnings implies a year-over-year decline of 3.6%, whereas its 2026 earnings estimate suggests year-over-year growth of 5.4%. The estimates for 2025 and 2026 have been southbound in the past 30 days. PEP stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CocaCola Company (The) (KO): Free Stock Analysis Report PepsiCo, Inc. (PEP): Free Stock Analysis Report Keurig Dr Pepper, Inc (KDP): Free Stock Analysis Report

Can Snowflake's Gen2 Launch Drive Strong Product Revenue Growth?
Can Snowflake's Gen2 Launch Drive Strong Product Revenue Growth?

Globe and Mail

time28 minutes ago

  • Globe and Mail

Can Snowflake's Gen2 Launch Drive Strong Product Revenue Growth?

Snowflake 's SNOW data warehouse platform has been gaining traction as enterprises increasingly rely on scalable, cloud native infrastructure to unify, analyze and share large volumes of data. Snowflake supports diverse workloads, ranging from business intelligence and data engineering to machine learning and AI. SNOW's compute engine, the Standard Warehouse, has been a critical driver for platform engagement and query performance across its data warehouse platform. Standard Warehouse supports high-throughput analytical workloads that power BI dashboards, batch jobs and AI applications across Snowflake's enterprise base. Snowflake recently launched Standard Warehouse – Generation 2 (Gen2), which delivers up to 2.1X faster analytics performance and 1.9X faster execution compared to the existing platforms. The upgrade introduces a new execution engine and next-gen hardware, reducing query latency without requiring changes to customer workloads. Snowflake's Gen2 upgrade reflects its continued investment in core performance infrastructure. SNOW's innovative portfolio is driving clientele. In the first quarter of fiscal 2026, Snowflake added 451 new customers, bringing the total to 11,578 (up 19% year over year). Snowflake maintained a net revenue retention rate of 124%, implying strong expansion within its existing base. Expanding customer base is driving product revenues, which hit $997 million in the first quarter of fiscal 2026, reflecting 26% year-over-year growth. The figure beat the Zacks Consensus Estimate by 6.71%. As demand grows for faster, cost-effective data processing across enterprise and AI workloads, Snowflake expects Gen2 to contribute significantly to its consumption-based revenue growth. Snowflake Faces Stiff Competition Snowflake's data warehouse platform faces intense competition from Amazon AMZN and Microsoft MSFT, both of which are strengthening their cloud data infrastructure and analytics capabilities. Amazon is advancing its position through Amazon Redshift and Redshift Serverless, which allow enterprises to scale analytics workloads without managing clusters. Redshift integrates with AWS's AI services like SageMaker and Bedrock, helping customers run ML models and generative AI applications directly within the data warehouse. Amazon's serverless innovation aligns with growing enterprise demand for elastic and AI-ready infrastructure. Microsoft is reinforcing its presence in enterprise data with Microsoft Fabric, a unified analytics platform that combines Synapse, Power BI, and Data Factory with AI integrations. Fabric supports real-time analytics and large language model workloads, enabling seamless data collaboration across business teams. Microsoft's tightly integrated stack and expanding AI capabilities are positioning it as a formidable player in next-gen data infrastructure. SNOW's Share Price Performance, Valuation and Estimates Snowflake shares have appreciated 36.5% year to date, outperforming the broader Zacks Computer & Technology sector's return of 1.7% and the Zacks Internet Software industry's increase of 13.2%. SNOW's YTD Price Performance Image Source: Zacks Investment Research Snowflake stock is trading at a premium, with a forward 12-month Price/Sales of 14.48X compared with the industry's 5.69X. SNOW has a Value Score of F. SNOW's Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for second-quarter fiscal 2026 earnings is pegged at 26 cents per share, unchanged over the past 30 days, indicating 44.44% year-over-year growth. Snowflake Inc. Price and Consensus The consensus mark for SNOW's fiscal 2026 earnings is pegged at $1.06 per share, which has declined by 8.5% over the past 30 days. The figure indicates a 27.71% increase year over year. Snowflake currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Snowflake Inc. (SNOW): Free Stock Analysis Report

Should You Buy Nio Stock Right Now?
Should You Buy Nio Stock Right Now?

Globe and Mail

time36 minutes ago

  • Globe and Mail

Should You Buy Nio Stock Right Now?

Nio (NYSE: NIO) is reporting an increase in deliveries and vehicle margins. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » *Stock prices used were the afternoon prices of June 6, 2025. The video was published on June 8, 2025. Should you invest $1,000 in Nio right now? Before you buy stock in Nio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store